BRANFORD, Conn. / Sep 19, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024.
Quantum-Si’s management team will provide updates on the Company’s market opportunities, provide deeper insights into the technology roadmap including new instrument offerings and present data on novel uses of the company’s detection technology to applications beyond Next-Generation Protein Sequencing™.
The event will be live streamed over the internet and a question-and-answer session will follow the formal presentations.
EVENT DETAILS:
WHEN: Wednesday, November 20, 2024 | 10 AM – 12 PM EST
WHERE: Westin NY Times Square, 270 West 43rd Street, New York, NY, 10036
REGISTRATION LINK (both in-person & virtual): Quantum-Si Investor & Analyst Event
Investors interested in attending should contact QSI investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it.. All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Quantum-Si’s website at https://ir.quantum-si.com/. The archived webcast will be available for at least 30 days following the event.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$1.32 |
| Daily Change: | 0.01 0.76 |
| Daily Volume: | 5,279,765 |
| Market Cap: | US$205.870M |
December 20, 2024 December 04, 2024 November 21, 2024 November 20, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
